**Aim:** New antidiabetic drugs are required to be evaluated in cardiovascular outcome trials (CVOTs). Few of these are direct comparisons between new drugs, so we performed a network meta-analysis to compare the new drug classes in terms of cardiovascular outcomes.

**Method:** We searched for CVOTs involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes using major adverse cardiovascular events (MACE) and mortality as endpoints. Network meta-analysis was performed using random-effects model in R.

**Results:** 13 CVOTs with a total 116,746 patients were included (*[Figure 1](#fig1){ref-type="fig"}*). GLP-1 RAs and SGLT-2 inhibitors significantly lowered the risk of MACE (OR 0.87, 95% CI \[0.82--0.94\] and OR 0.89, 95% CI \[0.82--0.97\]), all-cause mortality (OR 0.90, 95% CI \[0.82--0.99\] and OR 0.84, 95% CI \[0.76--0.93\]), heart failure (OR 0.87, 95% CI \[0.82--0.93\] and OR 0.70, 95% CI \[0.62--0.80\]), and renal composite outcome (OR 0.85, 95% CI \[0.75--0.97\] and OR 0.63, 95% CI \[0.55--0.72\]) when compared to placebo (*[Figure 2](#fig2){ref-type="fig"}*). GLP-1 RAs reduced nonfatal stroke (OR 0.88, 95% CI \[0.77--0.99\]), while SGLT-2 inhibitors reduced cardiovascular mortality (OR 0.83, 95% CI \[0.72--0.96\]). In contrast, DPP-4 inhibitors did not significantly alter the risk of these outcomes.
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**Conclusion:** GLP-1 RAs and SGLT-2 inhibitors both reduce MACE, heart failure, renal composite outcome, and all-cause mortality when compared to placebo. DPP-4 inhibitors did not show any cardiovascular benefits. Our findings support using SGLT-2 inhibitors and GLP-1 RAs for diabetic patients with high cardiovascular risk.
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